Clinical trials: Epithelial Ovarian
Epithelial Ovarian Cancer, Quality of Life
Women Surviving Ovarian Cancer
The purpose of this study is to help us learn more about how women who have had or now have ovarian cancer are doing 5 years or more from their diagnosis.
- Conditions
- Epithelial Ovarian Cancer, Quality of Life, Survivorship
- Trial name
- NCT00596349
- Testing
- questionnaires
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Malignant Epithelial Mesothelioma, Adenocarcinoma of the Pancreas
Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment
This clinical trial will evaluate the safety and tolerability of CRS 207 an investigational product that is a weakened form (attenuated) of Listeria monocytogenes, a type of bacteria that is commonly found in the environment.
- Conditions
- Malignant Epithelial Mesothelioma, Adenocarcinoma of the Pancreas, Carcinoma, Non-Small-Cell Lung, Adenocarcinoma of the Ovaries
- Trial name
- NCT00585845
- Testing
- CRS-207, Live-attenuated Listeria monocytogenes expressing human Mesothelin
- Where
- 4 sites in United States, Israel
- Volunteers
- 17 people
- Sponsor
- Anza Therapeutics, Inc.
Ovarian Cancer
Docetaxel and Oxaliplatin in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and oxaliplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells.
- Trial name
- NCT00075543
- Testing
- docetaxel, oxaliplatin
- Where
- 5 sites in France
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Ovarian Carcinoma
Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer (EOC): A Phase III Randomized Study
To determine the impact of Neoadjuvant chemotherapy on surgical debulking rate, overall and disease-free survival and quality of life (QOL) in patients with advanced EOC.
- Trial name
- NCT00715286
- Testing
- timing of surgery
- Where
- India
- Volunteers
- 180 people
- Sponsor
- All India Institute of Medical Sciences
Ovarian Neoplasms
A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma
The study will compare the pharmacokinetic profile of OvaRex MAb-B43.13 ascites fluid product and OvaRex MAb-B43.13 cell culture product.
- Trial name
- NCT00034138
- Testing
- oregovomab
- Where
- 8 sites in United States
- Volunteers
- 24 people
- Sponsor
- Unither Pharmaceuticals
Ovarian Neoplasms
Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian Carcinoma
In this study, patients will be randomized to one of three dose regimen groups. Each dose of OvaRex MAb-B43.13 is 2 mg by slow intravenous administration. Group 1 will receive two doses, one month apart.
- Trial name
- NCT00034372
- Testing
- oregovomab
- Where
- 17 sites in United States, Canada
- Volunteers
- 102 people
- Sponsor
- Unither Pharmaceuticals
Epithelial Ovarian Cancer
Treatment of Paclitaxel Plus Carboplatin Followed by Gemcitabine Plus Carboplatin for Patients With Epithelial Ovarian Cancer
The purpose of this study is to evaluate the efficacy of paclitaxel and carboplatin followed by gemcitabine and carboplatin therapy for patients with epithelial ovarian cancer.
- Trial name
- NCT00490711
- Testing
- gemcitabine, carboplatin, paclitaxel
- Where
- Slovakia
- Volunteers
- 7 people
- Sponsor
- Eli Lilly and Company
Epithelial Ovarian Carcinoma, Figo Stage IIIC
Intraperitoneal Hyperthermic Chemotherapy in Epithelial Ovarian Carcinoma
Phase II to study results and morbidity of intra peritoneal hyper-thermic chemotherapy as consolidation therapy in patients with FIGO stage IIIC epithelial ovarian carcinoma treated by surgery and a total of 6 cycles of platinum…
- Trial name
- NCT00349505
- Testing
- hyper thermic chemo + surgery
- Where
- France
- Volunteers
- 67 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum, Platinum Sensitve Relapse
Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer, Cancer of the Fallopian Tube or Peritoneum
Patients with epithelial ovarian cancer, fallopian tube or peritoneal cancer who receive surgical cytoreduction and platinum/taxane containing chemotherapy have a significant chance of entering complete clinical remission but…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum, Platinum Sensitve Relapse, Anemia
- Trial name
- NCT00189371
- Testing
- paclitaxel, carboplatin, epoetin alpha
- Where
- Germany
- Volunteers
- 300 people
- Sponsor
- AGO Study Group